In conclusion, our study revealed the low expression pattern of HSP90AA1 in ccRCC, validated its clinical prognostic value, and revealed a new mechanism by which HSP90AA1 inhibits the proliferation and metastasis of ccRCC by interacting with FBXO7 to promote CADM1 expression and suppress the PI3K-AKT signaling pathway (Fig. 8). This evidence concerns the gene FBXO7 and nonpapillary renal cell carcinoma.